BUY Supriya Lifescience Limited — Madhu Bansal
byMadhu BansalHorizon: NA (inferred Swing (≤2wk))29 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Supriya Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2026
NewsGoogle News·25 Sept · 4d ago
1 advisor has an active short-term BUY call on this stock
Advisor consensus · adjacent horizon·6 Jul · 3mo ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Supriya Lifescience
- BUY — Madhu Bansal11 Nov 2026 · ~2 weeks · target ₹725 · SL hit
- BUY — Kush Bohra29 Sept 2026 · ~2 weeks · target ₹1,020 · SL hit
- BUY — Om Mehra, SAMCO Securities28 Sept 2026 · ~2 weeks · target ₹1,060 · SL hit
- BUY — Dharmesh Shah, ICICI Securities24 Sept 2026 · ~2 weeks · target ₹1,011 · Target hit
- BUY — Om Mehra, SAMCO Securities21 Sept 2026 · ~2 weeks · target ₹980 · Target hit
More from Madhu Bansal
- BUY Eris Lifesciences13 Nov 2026 · ~2 weeks · target ₹1,450 · Active
- BUY Nazara Technologies13 Nov 2026 · ~2 weeks · target ₹467 · Active
- BUY Signatureglobal (India)12 Nov 2026 · ~2 weeks · target ₹835 · Active
- BUY Shilpa Medicare12 Nov 2026 · ~2 weeks · target ₹1,050 · Active
- BUY Supriya Lifescience11 Nov 2026 · ~2 weeks · target ₹725 · SL hit

